中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2010年
6期
415-419
,共5页
冯宪光%姚文环%刘艳%孙克任
馮憲光%姚文環%劉豔%孫剋任
풍헌광%요문배%류염%손극임
二十二碳六烯酸%H22细胞%HeLa细胞%U251细胞%Bcl-2%Bax%Caspase-3
二十二碳六烯痠%H22細胞%HeLa細胞%U251細胞%Bcl-2%Bax%Caspase-3
이십이탄륙희산%H22세포%HeLa세포%U251세포%Bcl-2%Bax%Caspase-3
DHA%H22 cell line%HeLa cell line%U251 cell line%Bcl-2%Bax%Caspase-3
目的 探讨二十二碳六烯酸(DHA)复合物的抗癌作用及其作用机制.方法 建立H22小鼠肝癌细胞的移植瘤动物模型,观察DHA复合物的体内抑瘤作用,采用体外细胞培养的方法 ,观察DHA复合物对宫颈癌HeLa细胞和胶质瘤U251细胞的体外抑瘤作用.采用电镜和荧光显微镜观察细胞形态的变化.Western blot法测定移植瘤组织中caspase-3蛋白的表达,逆转录聚合酶链反应(RT-PCR)检测HeLa细胞和U251细胞中Bel-2和Bax mRNA的表达.结果 DHA复合物对小鼠H22细胞移植瘤有明显的抑瘤作用,其低、中、高剂量组的抑瘤率分别为37.62%、48.55%和58.63%.在体外,随着剂量的增加,DHA复合物对HeLa细胞和U251的生长抑制率逐渐增高,Hela细胞的IC50为0.9814 μg/ml,U251细胞的IC50为0.3746 μg/ml.DHA复合物处理后,移植瘤细胞的细胞核呈分叶状,可见大小不等、致密的凋亡小体;HeLa细胞的细胞核内可见致密浓染的黄绿色荧光和碎片,分布在核周边,呈肾形或者半月形,核固缩,趋于碎裂.与CMC组比较,DHA复合物能明显促进caspase-3蛋白的表达,且DHA复合物剂最越高,caspase-3蛋白的表达升高越明显.DHA复合物能下调U251细胞中Bcl-2 mRNA的表达,上调Bax mRNA的表达,与CMC组比较,差异均有统计学意义(均P<0.01).结论 DHA复合物在体内外对多种肿瘤细胞有抑制作用,其抑瘤作用可能是通过抑制Bcl-2的表达、促进Bax和caspase-3的表达实现的.
目的 探討二十二碳六烯痠(DHA)複閤物的抗癌作用及其作用機製.方法 建立H22小鼠肝癌細胞的移植瘤動物模型,觀察DHA複閤物的體內抑瘤作用,採用體外細胞培養的方法 ,觀察DHA複閤物對宮頸癌HeLa細胞和膠質瘤U251細胞的體外抑瘤作用.採用電鏡和熒光顯微鏡觀察細胞形態的變化.Western blot法測定移植瘤組織中caspase-3蛋白的錶達,逆轉錄聚閤酶鏈反應(RT-PCR)檢測HeLa細胞和U251細胞中Bel-2和Bax mRNA的錶達.結果 DHA複閤物對小鼠H22細胞移植瘤有明顯的抑瘤作用,其低、中、高劑量組的抑瘤率分彆為37.62%、48.55%和58.63%.在體外,隨著劑量的增加,DHA複閤物對HeLa細胞和U251的生長抑製率逐漸增高,Hela細胞的IC50為0.9814 μg/ml,U251細胞的IC50為0.3746 μg/ml.DHA複閤物處理後,移植瘤細胞的細胞覈呈分葉狀,可見大小不等、緻密的凋亡小體;HeLa細胞的細胞覈內可見緻密濃染的黃綠色熒光和碎片,分佈在覈週邊,呈腎形或者半月形,覈固縮,趨于碎裂.與CMC組比較,DHA複閤物能明顯促進caspase-3蛋白的錶達,且DHA複閤物劑最越高,caspase-3蛋白的錶達升高越明顯.DHA複閤物能下調U251細胞中Bcl-2 mRNA的錶達,上調Bax mRNA的錶達,與CMC組比較,差異均有統計學意義(均P<0.01).結論 DHA複閤物在體內外對多種腫瘤細胞有抑製作用,其抑瘤作用可能是通過抑製Bcl-2的錶達、促進Bax和caspase-3的錶達實現的.
목적 탐토이십이탄륙희산(DHA)복합물적항암작용급기작용궤제.방법 건립H22소서간암세포적이식류동물모형,관찰DHA복합물적체내억류작용,채용체외세포배양적방법 ,관찰DHA복합물대궁경암HeLa세포화효질류U251세포적체외억류작용.채용전경화형광현미경관찰세포형태적변화.Western blot법측정이식류조직중caspase-3단백적표체,역전록취합매련반응(RT-PCR)검측HeLa세포화U251세포중Bel-2화Bax mRNA적표체.결과 DHA복합물대소서H22세포이식류유명현적억류작용,기저、중、고제량조적억류솔분별위37.62%、48.55%화58.63%.재체외,수착제량적증가,DHA복합물대HeLa세포화U251적생장억제솔축점증고,Hela세포적IC50위0.9814 μg/ml,U251세포적IC50위0.3746 μg/ml.DHA복합물처리후,이식류세포적세포핵정분협상,가견대소불등、치밀적조망소체;HeLa세포적세포핵내가견치밀농염적황록색형광화쇄편,분포재핵주변,정신형혹자반월형,핵고축,추우쇄렬.여CMC조비교,DHA복합물능명현촉진caspase-3단백적표체,차DHA복합물제최월고,caspase-3단백적표체승고월명현.DHA복합물능하조U251세포중Bcl-2 mRNA적표체,상조Bax mRNA적표체,여CMC조비교,차이균유통계학의의(균P<0.01).결론 DHA복합물재체내외대다충종류세포유억제작용,기억류작용가능시통과억제Bcl-2적표체、촉진Bax화caspase-3적표체실현적.
Objective To study the anticancer effect in vitro and in vivo and mechanism of DHA compound. Methods Cervical cancer cell line HeLa cells, glioma cell line U251 cells and mouse hepatoma H22 tumor were used in this study. Transmission electron microscopy and flurescence microscopy were used to observe the morphological changes of cell apoptosis. Western blot was used to detect the expression of caspase-3. RT-PCR was used to determine the effect on Bcl-2 and Bax mRNA transcription in U251. Results Antitumor effect was observed in vivo and in vitro. Typical morphological changes were seen in cancer cells. The level of caspase-3 was significantly increased and the content of Bcl-2 mRNA was decreasd significantly, while the content of Bax mRNA was significantly increased in the U251 cells after treatment with DHA compound. Conclusion DHA compound can inhibit the growth of some types of tumors and the increase of caspase-3 and Bax mRNA and decrease of Bcl-2 mRNA may be involved in its mechamism of action.
